title: [Effect on bone structure and strength by novel anti-osteoporotic agents].
abstract: Recent progress in understanding molecular processes underlying osteoporosis has resulted in the development of several new anti-osteoporotic agents that are currently being explored in clinical trials. Denosumab, a monoclonal antibody directed against RANKL, has just approved in Japan and some additional new therapies are lining up for clinical approval in the coming years. Potential agents include cathepsin K inhibitor and sclerostin. Here, I will provide a short overview on these three agents focusing on their effect on structural properties and bone strength.
authors.affiliation: Department of Nuclear Medicine, Kawasaki Medical School, Japan.
authors.forename: Teruki
authors.initials: T
authors.lastname: Sone
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001842:Bone and Bones / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D050071:Bone Density Conservation Agents